Monitoring Natural Killer Cells in Multiple Sclerosis Patients Treated With Fingolimod: a Monocentric, Prospective, One Year, Baseline-to-treatment, Open-label Single Group Pilot Trial
Phase of Trial: Phase IV
Latest Information Update: 05 Dec 2018
Price : $35 *
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics
- 28 Nov 2018 Status changed from active, no longer recruiting to discontinued.
- 31 Aug 2018 Biomarkers information updated
- 21 Dec 2017 Planned End Date changed from 1 Nov 2017 to 1 Jun 2018.